Similar articles

• [Current status and issues in hematopoietic stem cell transplantation].

  Harada M. Harada M. Fukuoka Igaku Zasshi. 2007 Feb;98(2):35-47. Fukuoka Igaku Zasshi. 2007. PMID: 17396570 Review. Japanese. No abstract available.
• Sirolimus-containing graft-versus-host disease prophylaxis in patients with lymphoma.

  Mehta J. Mehta J. J Clin Oncol. 2009 Oct 1;27(28):e138; author reply e139-40. doi: 10.1200/JCO.2009.23.9483. Epub 2009 Aug 31. J Clin Oncol. 2009. PMID: 19720890 No abstract available.
• Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up.

  Björkstrand B, Iacobelli S, Hegenbart U, Gruber A, Greinix H, Volin L, Narni F, Musto P, Beksac M, Bosi A, Milone G, Corradini P, Goldschmidt H, de Witte T, Morris C, Niederwieser D, Gahrton G. Björkstrand B, et al. J Clin Oncol. 2011 Aug 1;29(22):3016-22. doi: 10.1200/JCO.2010.32.7312. Epub 2011 Jul 5. J Clin Oncol. 2011. PMID: 21730266
• A decade of progress in allogeneic hematopoietic cell transplantation: 1990-2000.

  Stockerl-Goldstein KE, Blume KG. Stockerl-Goldstein KE, et al. Adv Cancer Res. 2001;81:1-59. doi: 10.1016/s0065-230x(01)81001-0. Adv Cancer Res. 2001. PMID: 11430593 Review. No abstract available.
• Progress in graft-versus-host disease.

  Chao NJ. Chao NJ. J Hematother Stem Cell Res. 2000 Jun;9(3):295-6. doi: 10.1089/15258160050079380. J Hematother Stem Cell Res. 2000. PMID: 10894349 No abstract available.